The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD) data, as well as updated safety data from the ongoing Phase 1 studies of CLYM116 in healthy ...

Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in ...

NEW ORLEANS--(BUSINESS WIRE)--In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) ...

WELLESLEY HILLS, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...